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Recombinant Immune Interferon Increases
Immunoglobulin G Fc Receptors
on Cultured Human Mononuclear Phagocytes
PAUL M. GUYRE, PETER M. MORGANELLI, and RENEE MILLER, Department of
Physiology, Dartmouth Medical School, Hanover, New Hampshire 03755

A B S T R A C T Although recent studies suggest that in- plexes (1), phagocytosis (2), antibody-dependent celterferons can increase the number of IgG Fc receptor lular cytotoxicity (3), and tumoricidal actions in vivo
(FcR'y) sites on mouse macrophages, direct assessment of monoclonal antibodies (4). FcRy probably also play
of similar effects on human mononuclear phagocytes
is lacking. We therefore measured the specific binding
60
of 125.- and fluorescein-labeled IgGl to human mono(B)
(A)
with
vitro
C
cytes and leukemic cell lines after culture in
E
highly purified human interferons. We report that
L
L
natural and recombinant human 'y-interferon causes
a dramatic (nearly 10-fold) increase in the number of
N
U
N
FcR-y on normal human monocytes and on the human
B
cell lines HL-60 and U-937. Alpha and ,B-interferons
E
R
cause a modest but significant increase in these receptors. This report demonstrates that 'v-interferon acts
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directly on human mononuclear phagocytes to inxJDO
6
crease FcR-y sites, it identifies a qualitative difference
(D)
I I(C)
in the physiologic actions of human type I and type
E
L
II interferons, and it suggests that HL-60 and U-937
NL
cells will be important models for further study of the
N
molecular mechanisms of interferon action. The results
U
N
reported here could also be the basis for a bioassay to
B
'-inE
assess the pharmacokinetics and variability of
R
terferon action on monocytes of individual patients
during treatment in vitro and in vivo.
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INTRODUCTION
Receptors for the Fc portion of IgG (Fc receptors or
FcR'y)l are important for normal mononuclear phagocyte functions including clearance of immune comReceived for publication 13 April 1983.
' Abbreviations used in this paper: FcR-y, receptors for
the Fc portion of IgG; FITC, fluorescein isothiocyanate.

FIGURE 1 y-Interferon augmentation of human monocyte
FcRy. 1 X 107 monocytes were cultured for 48 h in 120-ml
teflon vessels (Scientific Specialties, Randallstown, MD) in
10 ml of RPMI 1640 plus 5 X 10-5 M 2-mercaptoethanol
plus 10% autologous serum, with (B and D) or without (A
and C) 10 U/ml recombinant 'y-interferon. FITC-IgG binding was assayed by flow cytometry as described. FcRy increased from a mean of 18,000 sites/cell for control cultures
(A) to 162,000 sites/cell following interferon treatment (B).
Nonsaturable binding of the fluorescent IgG was identical
for both treatments (C and D).
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a role in several autoimmune diseases (5), in B cell
mitogenesis (6) and in prostaglandin and collagenase
release (7) by macrophages. Although lymphokines
stimulate some of these cellular functions, both the
identification of the active moiety and the mechanisms
underlying the effects of lymphokines are not well
known. Defective expression of FcR'y on macrophages
from C3H/HeJ mice is corrected by murine f,- and

,y-interferons (8), and murine a-interferon has similar
activity (9). The augmentation of human monocyte
FcR'y, which we have described (10), is one of the
largest lymphokine-induced macrophage activation
effects reported to date (11). During purification of the
"Fc receptor-augmenting factor" we noted many
physicochemical similarities to immune ("y) interferon,
and we now show that human -y-interferon is a potent
Fc receptor-augmenting factor, which probably accounts for the activity we identified in crude lymphokine preparations.

METHODS
Cells. HL-60 and U-937 cells (gifts of Dr. R. Gallo, National Cancer Institute, and Dr. P. Ralph, Sloan Kettering
Institute, respectively) were cultured in RPMI 1640 (KC
Biological, Inc., Lenexa, KS) plus 10% fetal bovine serum
(Sterile Systems, Inc., Logan, UT). Human monocytes were
obtained by adherence to plastic (7) and subsequent release
by incubation for 2 h at 4°C. These cultures contained 8494% monocytes as determined by morphology and specific
staining with monoclonal antibody 63D3 (12).
Analysis of Fc receptors. We (10) and others (13) have
characterized Fc recelptors on human monocytes, HL-60
cells (14), and U-937 cells (15) using a standard radiolabeled
IgGI-binding assay. In this report we also use a flow cytometric method for measurement of Fc receptors (16). Human IgGI was purified from the plasma of a patient with
myeloma (kindly provided by Dr. G. Cornwell, Dartmouth
Medical School) radioiodinated, and '25I-IgG1-binding to
HL-60 and U-937 cells was quantified by slight modification
(see Figs. 1 and 2 legends) of methods previously reported
(10, 14). Fluorescein isothiocyanate-labeled IgGI (FITCIgGl; fluorescein/protein ratio 3.8) was prepared according
to Goding (17). For flow cytometric analysis, cells cultured
in human serum were washed five times with 1 ml RPMI
1640, and stained for 2 h at 37°C with 4 X 108 M FITCIgGI, in the absence or presence of 4 X 10-6 M unlabeled
IgG (to assess nonsaturable binding). Cells were then washed
twice with ice-cold Dulbecco's phosphate-buffered saline
containing 2 mg/ml bovine serum albumin (PBS-BSA), resuspended in PBS-BSA, and analyzed on a Cytofluorograf
System 50H (Ortho Diagnostic Systems, Inc., Westwood,
MA) using 488 nm laser excitation. To convert the fluorescence values obtained from the flow cytometer to molecules

of IgG bound per cell, U-937 cells which received identical
treatment, were labeled with FITC-IgGl for assay by fluorescence as above and with "25I-IgG1 for assay of IgGI binding by our standard assay (14). Fluorescence was converted
to IgG per cell according to the method of Titus et al. (16).
Interferons. Human a-, ,l-, and 'y-interferons (kindly
provided by Dr. P. Weck, Genentech, Inc.) were produced
in bacterial cultures following cloning of the appropriate
genes into Escherichia coli (18-20). The interferons used in
this study were >95% pure as determined by gel electrophoresis and silver staining (21). For treatment of cells, interferons were diluted in Iscove's-modified Dulbecco's-modified Eagle's medium (KC Biological, Inc., Lenexa, KS).

RESULTS

Fig. 1 shows the immunofluorescence due to binding
of FITC-labeled IgGI to Fc receptors on normal human monocytes following 48-h culture with or without
10 U/ml y-interferon. Similar results were obtained
with monocytes from each of 14 normal donors. Fc
receptor sites increased dramatically on the y-interferon-treated monocytes, and ranged on individual
cells from the control level (15,000-35,000 sites) to
>200,000 sites/cell. This marked heterogeneity will
permit cell sorting for cells with high or low FcRy, to
evaluate the relationship between the number of FcR'y
sites, and FcR-y-dependent functions. The maximal
effect is at 48-72 h using 10-100 antiviral U/ml yinterferon (a-interferon as standard), with a half-maximal effect between 1 and 5 U/ml. We have found
flow cytometry to be superior to radioligand binding
for analyses of monocytes, since it permits computer
regions to be set for independent evaluation of lymphocytes and monocytes without their prior physical
separation. Since our monocyte preparations contained
6-16% lymphocytes in 14 experiments, we have not
ruled out the possibility that the lymphocyte is important for the FcR-y augmentation reported here.
However, since we found identical effects at all levels
of lymphocyte contamination, and direct effects on
HL-60 and U-937 cells (Fig. 2), this possibility seems
unlikely. Fig. 2 shows the specific binding of labeledIgGI to human monocytes, HL-60, and U-937 cells
after treatment for 16 h with various concentrations
of a-, ,B-, or -y-interferons. While 'y-interferon dramatically increased IgGl-binding to Fc receptors. aand ,B-interferons had minor but significant (P < 0.01)
effects. In four experiments, the dose that gave a halfmaximal increase in IgG binding ranged from 1 to 5

FIGURE 2 Concentration dependence of Fc receptor augmentation. 2.5 X 105 HL-60 or U-937
cells/well were cultured for 16 h in 200 ul complete medium in 96-well microtiter trays (Costar,
Data Packaging, Cambridge, MA). Human monocytes were cultured as described for Fig. 1
using 2 X 106 cells/ml per 30 ml teflon vessel. After incubation with interferons, U-937 and
HL-60 cells were labeled with '251-IgGL and the average number of IgG molecules bound per
cell was determined as previously described (14). Human monocytes were stained and analyzed
by flow cytometry as described. Fig. 2 shows the response to a-(A), #-(A), and 'Y-(-) interferon
for U-937 cells (2 A), HL-60 cells (2 B), and normal monocytes (2 C).
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U y-interferon/ml. The maximal increase after 16-h
treatment was obtained with -100 U/ml and ranged
from 4.8- to 7.4-fold. Alpha and beta interferons
caused only a 20-50% increase, even at concentrations
between 100 and 10,000 U/ml. The increased number
of Fc receptors was not accompanied by alterations
in cell size or proliferative rate, as determined by Coulter counts, cytocrits, and flow cytometric analysis of
cell size.
Scatchard analysis of IgGl binding by U-937 cells
following treatment for 40 h with a-, A3-, or y-interferons showed that while 10 U/ml y-interferon caused
an 8.5-fold increase in the number of FcRy, the binding affinity for IgG did not change significantly (ranging in three experiments from 5.5 X 108 M-1 to 2.7
X 10' M-1, independent of treatment).
We have found in other experiments that treatment
of U-937 cells with recombinant y-interferon results
in enhanced antibody-dependent cell-mediated cytotoxicity of chick erythrocytes, which is roughly proportional to the increase in FcR'y sites. Thus, treatment
with y-interferon alone is a sufficient stimulus for this
type of macrophage activation. However, a second
type of Fc receptor present on human neutrophils has
been described by Fleit et al. (26), who reported that
it is absent from HL-60 cells, U-937 cells, and human
monocytes. It will be irnportant for interpretation of
functional assays to determine whether this second Fc
receptor is expressed on interferon-treated cells.

introduce a new measure of human mononuclear
phagocyte function that may provide important information in diseases such as systemic lupus erythematosus, where there is an as yet poorly understood
defect in FcR function (5).
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